AURA BIOSCIENCES INC (AURA) Stock Price, Quote, News and Overview
NASDAQ:AURA - Nasdaq - US05153U1079 - Common Stock - Currency: USD
AURA Quote, Performance and Key Statistics
7.51
-0.12 (-1.57%)
The current stock price of AURA is 7.51 USD. In the past month the price decreased by -7.28%. In the past year, price decreased by -15.52%.
AURA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AURA
Company Profile
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The company is headquartered in Boston, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2021-10-29. The firm is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. The company is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. The company is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.
Company Info
AURA BIOSCIENCES INC
80 Guest Street
Boston MASSACHUSETTS US
CEO: Elisabet de los Pinos
Employees: 89
Company Website: https://aurabiosciences.com/
Investor Relations: https://ir.aurabiosciences.com/
Phone: 16175008864
AURA BIOSCIENCES INC / AURA FAQ
What is the stock price of AURA BIOSCIENCES INC today?
The current stock price of AURA is 7.51 USD. The price decreased by -1.57% in the last trading session.
What is the ticker symbol for AURA BIOSCIENCES INC stock?
The exchange symbol of AURA BIOSCIENCES INC is AURA and it is listed on the Nasdaq exchange.
On which exchange is AURA stock listed?
AURA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AURA BIOSCIENCES INC stock?
13 analysts have analysed AURA and the average price target is 22.27 USD. This implies a price increase of 196.54% is expected in the next year compared to the current price of 7.51. Check the AURA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AURA BIOSCIENCES INC worth?
AURA BIOSCIENCES INC (AURA) has a market capitalization of 375.12M USD. This makes AURA a Small Cap stock.
How many employees does AURA BIOSCIENCES INC have?
AURA BIOSCIENCES INC (AURA) currently has 89 employees.
What are the support and resistance levels for AURA BIOSCIENCES INC (AURA) stock?
AURA BIOSCIENCES INC (AURA) has a support level at 7.39 and a resistance level at 7.75. Check the full technical report for a detailed analysis of AURA support and resistance levels.
Should I buy AURA BIOSCIENCES INC (AURA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AURA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AURA, evaluating the profitability, health, valuation and growth aspects
- AURA BIOSCIENCES INC (AURA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AURA BIOSCIENCES INC (AURA) Sales and EPS estimates to see what analysts future expectations are.
- AURA BIOSCIENCES INC (AURA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AURA BIOSCIENCES INC (AURA) Insider and Institutional Ownership to learn about the owners and their transactions.
- AURA BIOSCIENCES INC (AURA) Stock Chart to make your own analysis
- AURA BIOSCIENCES INC (AURA) Latest news and press-releases to stay up to date.
Does AURA BIOSCIENCES INC (AURA) stock pay dividends?
AURA does not pay a dividend.
When does AURA BIOSCIENCES INC (AURA) report earnings?
AURA BIOSCIENCES INC (AURA) will report earnings on 2025-03-12, after the market close.
What is the Price/Earnings (PE) ratio of AURA BIOSCIENCES INC (AURA)?
AURA BIOSCIENCES INC (AURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.79).
What is the Short Interest ratio of AURA BIOSCIENCES INC (AURA) stock?
The outstanding short interest for AURA BIOSCIENCES INC (AURA) is 2.51% of its float. Check the ownership tab for more information on the AURA short interest.
AURA Technical Analysis
AURA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AURA. While AURA has a great health rating, there are worries on its profitability.
AURA Financial Highlights
Over the last trailing twelve months AURA reported a non-GAAP Earnings per Share(EPS) of -1.79. The EPS increased by 9.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.53% | ||
| ROE | -47.64% | ||
| Debt/Equity | 0 |
AURA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to AURA. The Buy consensus is the average rating of analysts ratings from 13 analysts.